Novavax: Switzerland health authorities recommends Nuvaxovid

(CercleFinance.com) - Novavax yesterday announced that Switzerland's Federal Office of Public Health (FOPH) has recommended Nuvaxovid™(NVX-CoV2373) as a heterologous and homologous booster for active immunisation to prevent coronavirus disease in adults aged 18 and older.


The FOPH now recommends use of Nuvaxovid as an adult booster regardless of previous vaccine history as part of its autumn 2022 COVID-19 vaccine booster campaign.

The recommendation followed presentation of data describing the durability and breadth of immune response following heterologous and homologous boosting.

The recommendation for Novavax's protein-based vaccine follows the expanded temporary authorisation of Nuvaxovid as a heterologous and homologous booster dose for adults aged 18 and older in September 2022 from Swissmedic, the Swiss Agency for Therapeutic Products.

Copyright (c) 2022 CercleFinance.com. All rights reserved.